{"nctId":"NCT01962441","briefTitle":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","startDateStruct":{"date":"2013-09-24","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":601,"armGroups":[{"label":"SOF+RBV 16 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV+Peg-IFN 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV","Drug: Peg-IFN"]},{"label":"Retreatment Substudy","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV","Drug: Peg-IFN"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]},{"name":"Peg-IFN","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female, age greater than or equal to 18 years.\n* Confirmed chronic HCV infection.\n* Subjects will have cirrhosis status assessment; liver biopsy may be required.\n* Genotype 2 subjects must have cirrhosis of the liver to be eligible.\n* Treatment-naive or prior treatment failure to ≥12 weeks of an interferon- based regimen that was not discontinued prematurely due to an adverse event\n* Infection with HCV genotype 2 or 3 as determined at Screening\n* Body mass index (BMI) greater than or equal to 18 kg/m\\^2\n* Screening laboratory values within predefined thresholds.\n* Liver imaging (e.g., ultrasound) within 6 months of Baseline/Day 1 is required in cirrhotic patients to exclude hepatocellular carcinoma (HCC). In the event of intrahepatic lesions, triple phase CT scan or MRI should be performed to exclude HCC.\n* Subject must be of generally good health as determined by the Investigator.\n\nKey Exclusion Criteria:\n\n* Prior use of any other inhibitor of the HCV nonstructural protein (NS)5B polymerase\n* Pregnant or nursing female or male with pregnant female partner\n* History of any other clinically significant chronic liver disease.\n* HIV or chronic hepatitis B virus (HBV) infection.\n* Malignancy with the exception of certain resolved skin cancers.\n* Chronic use of systemically administered immunosuppressive agents.\n* Clinically-relevant drug or alcohol abuse.\n* History of solid organ transplantation.\n* Current or prior history of clinical hepatic decompensation.\n* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.\n* Known hypersensitivity to interferon, RBV, the study investigational medicinal product, the metabolites, or formulation excipients.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"85.4","spread":null},{"groupId":"OG002","value":"92.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"85.9","spread":null},{"groupId":"OG002","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"84.4","spread":null},{"groupId":"OG002","value":"93.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"20.1","spread":null},{"groupId":"OG002","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"53.5","spread":null},{"groupId":"OG002","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"91.9","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA at Weeks 1, 2, 4, 8, and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.658"},{"groupId":"OG001","value":"2.08","spread":"0.749"},{"groupId":"OG002","value":"1.81","spread":"0.576"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"0.436"},{"groupId":"OG001","value":"1.45","spread":"0.487"},{"groupId":"OG002","value":"1.32","spread":"0.342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"0.156"},{"groupId":"OG001","value":"1.21","spread":"0.287"},{"groupId":"OG002","value":"1.16","spread":"0.085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.021"},{"groupId":"OG001","value":"1.15","spread":"0.100"},{"groupId":"OG002","value":"1.15","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.000"},{"groupId":"OG001","value":"1.17","spread":"0.318"},{"groupId":"OG002","value":"1.15","spread":"0.000"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.18","spread":"0.559"},{"groupId":"OG001","value":"-4.15","spread":"0.664"},{"groupId":"OG002","value":"-4.46","spread":"0.556"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.86","spread":"0.661"},{"groupId":"OG001","value":"-4.78","spread":"0.714"},{"groupId":"OG002","value":"-4.96","spread":"0.661"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.671"},{"groupId":"OG001","value":"-5.02","spread":"0.735"},{"groupId":"OG002","value":"-5.12","spread":"0.699"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"0.684"},{"groupId":"OG001","value":"-5.08","spread":"0.708"},{"groupId":"OG002","value":"-5.12","spread":"0.691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.15","spread":"0.686"},{"groupId":"OG001","value":"-5.05","spread":"0.788"},{"groupId":"OG002","value":"-5.12","spread":"0.691"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing On-Treatment Virologic Failure","description":"On-treatment virologic failure was defined as:\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Relapse","description":"Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"4.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":196},"commonTop":["Fatigue","Headache","Insomnia","Nausea","Rash"]}}}